Neoplasia,
Journal Year:
2024,
Volume and Issue:
51, P. 100985 - 100985
Published: March 12, 2024
Alterations
in
cellular
metabolism
are
important
hallmarks
of
glioblastoma(GBM).
Metabolic
reprogramming
is
a
critical
feature
as
it
meets
the
higher
nutritional
demand
tumor
cells,
including
proliferation,
growth,
and
survival.
Many
genes,
proteins,
metabolites
associated
with
GBM
have
been
found
to
be
aberrantly
expressed,
which
may
provide
potential
targets
for
cancer
treatment.
Therefore,
becoming
increasingly
explore
role
internal
external
factors
metabolic
regulation
order
identify
more
precise
therapeutic
diagnostic
markers
GBM.
In
this
review,
we
define
characteristics
GBM,
investigate
specificities
such
targetable
vulnerabilities
resistance,
well
present
current
efforts
target
improve
standard
care.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(7), P. 1276 - 1276
Published: March 25, 2024
Despite
decades
of
research
and
the
best
up-to-date
treatments,
grade
4
Glioblastoma
(GBM)
remains
uniformly
fatal
with
a
patient
median
overall
survival
less
than
2
years.
Recent
advances
in
immunotherapy
have
reignited
interest
utilizing
immunological
approaches
to
fight
cancer.
However,
current
immunotherapies
so
far
not
met
anticipated
expectations,
achieving
modest
results
their
journey
from
bench
bedside
for
treatment
GBM.
Understanding
intrinsic
features
GBM
is
crucial
importance
development
effective
antitumoral
strategies
improve
life
expectancy
conditions.
In
this
review,
we
provide
comprehensive
overview
distinctive
characteristics
that
significantly
influence
conventional
therapies
immune-based
approaches.
Moreover,
present
an
immunotherapeutic
currently
undergoing
clinical
evaluation
treatment,
specific
emphasis
on
those
advancing
phase
3
studies.
These
encompass
immune
checkpoint
inhibitors,
adoptive
T
cell
therapies,
vaccination
(i.e.,
RNA-,
DNA-,
peptide-based
vaccines),
virus-based
Finally,
explore
novel
innovative
future
prospects
field
Journal of Nanotheranostics,
Journal Year:
2025,
Volume and Issue:
6(1), P. 4 - 4
Published: Jan. 31, 2025
Regrettably,
despite
undeniable
advances
in
cancer
diagnosis
and
therapy,
primary
brain
(or
cancer)
remains
one
of
the
deadliest
forms
malignant
tumors,
where
glioblastoma
(GBM)
is
known
as
most
diffuse
glioma
astrocytic
lineage.
Fortunately,
to
improve
this
scenario,
remarkable
progress
nanotechnology
has
brought
new
promise
raised
expectations
treatment.
Nanomedicine,
principally
an
area
amalgamating
with
biology
medicine,
demonstrated
a
pivotal
role,
starting
earliest
detection
while
also
offering
novel
multimodal
therapy
alternatives.
In
vast
realm
nanotechnology,
nanozymes,
type
nanomaterial
intrinsic
enzyme-like
activities
characteristics
connecting
fields
nanocatalysts,
enzymology,
biology,
have
emerged
powerful
nanotools
for
theranostics.
Hence,
fascinating
field
research
experienced
exponential
growth
recent
years.
As
it
virtually
impossible
cover
all
literature
on
broad
domain
science
paper,
review
focuses
presenting
multidisciplinary
approach,
its
content
extending
from
fundamental
knowledge
nanozymes
enzyme-mimicking
catalysis
targeting
cancers.
Although
we
are
at
very
early
stages
research,
can
be
envisioned
that
strategic
development
theranostics
will
positively
offer
disruptive
nanoplatforms
future
nano-oncology.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Nov. 14, 2023
Tumor-associated
macrophages
(TAMs)
are
integral
to
the
tumor
microenvironment
(TME),
influencing
cancer
progression
significantly.
Attracted
by
cell
signals,
TAMs
exhibit
unparalleled
adaptability,
aligning
with
dynamic
milieu.
Their
roles
span
from
promoting
growth
and
angiogenesis
modulating
metastasis.
While
substantial
research
has
explored
fundamentals
of
TAMs,
comprehending
their
adaptive
behavior,
leveraging
it
for
novel
treatments
remains
challenging.
This
review
delves
into
TAM
polarization,
metabolic
shifts,
complex
orchestration
cytokines
chemokines
determining
functions.
We
highlight
complexities
TAM-targeted
focusing
on
adaptability
potential
variability
in
therapeutic
outcomes.
Moreover,
we
discuss
synergy
integrating
TAM-focused
strategies
established
treatments,
such
as
chemotherapy,
immunotherapy.
Emphasis
is
laid
pioneering
methods
like
reprogramming
immunotherapy
adoption
single-cell
technologies
precision
intervention.
synthesis
seeks
shed
light
TAMs’
multifaceted
cancer,
pinpointing
prospective
pathways
transformative
enhancing
modalities
oncology.
Genome Medicine,
Journal Year:
2023,
Volume and Issue:
15(1)
Published: July 11, 2023
Spatiotemporal
heterogeneity
originating
from
genomic
and
transcriptional
variation
was
found
to
contribute
subtype
switching
in
isocitrate
dehydrogenase-1
wild-type
glioblastoma
(GBM)
prior
upon
recurrence.
Fluorescence-guided
neurosurgical
resection
utilizing
5-aminolevulinic
acid
(5ALA)
enables
intraoperative
visualization
of
infiltrative
tumors
outside
the
magnetic
resonance
imaging
contrast-enhanced
regions.
The
cell
population
functional
status
tumor
responsible
for
enhancing
5ALA-metabolism
fluorescence-active
PpIX
remain
elusive.
close
spatial
proximity
5ALA-metabolizing
(5ALA
+)
cells
residual
disease
remaining
post-surgery
renders
5ALA
+
biology
an
early
a
priori
proxy
GBM
recurrence,
which
is
poorly
understood.
JCI Insight,
Journal Year:
2024,
Volume and Issue:
9(7)
Published: Feb. 22, 2024
The
efficacy
of
chimeric
antigen
receptor
T
cell
(CAR-T)
therapy
has
been
limited
against
brain
tumors
to
date.
CAR-T
cells
infiltrating
syngeneic
intracerebral
SB28
EGFRvIII
gliomas
revealed
impaired
mitochondrial
ATP
production
and
a
markedly
hypoxic
status
compared
with
ones
migrating
subcutaneous
tumors.
Drug
screenings
improve
metabolic
states
under
conditions
led
us
evaluate
the
combination
AMPK
activator
metformin
mTOR
inhibitor
rapamycin
(Met+Rap).
Met+Rap-pretreated
mouse
showed
activated
PPAR-γ
coactivator
1α
(PGC-1α)
through
inhibition
activation,
higher
level
spare
respiratory
capacity
than
those
pretreated
individual
drugs
or
without
pretreatment.
Moreover,
demonstrated
persistent
effective
antiglioma
cytotoxic
activities
in
condition.
Furthermore,
single
intravenous
infusion
significantly
extended
survival
mice
bearing
gliomas.
Mass
cytometric
analyses
highlighted
increased
glioma-infiltrating
Met+Rap
group,
fewer
Ly6c+CD11b+
monocytic
myeloid-derived
suppressor
Finally,
human
recapitulated
observations
murine
cells,
demonstrating
improved
functions
vitro
conditions.
These
findings
advocate
for
translational
clinical
exploration
trials.
Journal of Photochemistry and Photobiology,
Journal Year:
2023,
Volume and Issue:
13, P. 100161 - 100161
Published: Jan. 9, 2023
Glioblastomas
(GBM)
are
considered
one
of
the
most
aggressive
tumors
central
nervous
system.
The
standard
treatment
for
GBM-diagnosed
patients
implies
surgery,
followed
by
radio
and
chemotherapy,
with
a
survival
12
to
15
months
after
treatment.
Photodynamic
Therapy
(PDT)
is
an
alternative
approach
treating
several
diseases,
including
tumors.
study
PDT
treat
GBM
has
been
gaining
attention
over
last
few
years.
In
this
work,
we
reviewed
cellular
molecular
features
current
modalities
as
well
used
photosensitizers
GBM-PDT
reported
in
five
years,
such
porphyrins,
chlorins,
phthalocyanines,
also
their
precursors,
case
aminolaevulinic
acid.
Moreover,
analysis
targets,
mechanisms
mediating
response
resistance
PDT,
clinical
application
strategy
have
discussed.
Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
12
Published: Jan. 26, 2023
Glioblastoma
(GBM)
is
the
most
common
and
aggressive
form
of
malignant
glioma.
The
GBM
tumor
microenvironment
(TME)
a
complex
ecosystem
heterogeneous
cells
signaling
factors.
Glioma
associated
macrophages
microglia
(GAMs)
constitute
significant
portion
TME,
suggesting
that
their
functional
attributes
play
crucial
role
in
cancer
homeostasis.
In
GBM,
an
elevated
GAM
population
with
poor
prognosis
therapeutic
resistance.
Neoplastic
recruit
these
myeloid
populations
through
release
chemoattractant
factors
dysregulate
induction
inflammatory
programs.
GAMs
become
protumoral
advocates
production
variety
cytokines,
mediators,
growth
can
drive
proliferation,
invasion,
immune
evasion,
angiogenesis.
Among
factors,
cyclooxygenase-2
(COX-2)
its
downstream
product,
prostaglandin
E2
(PGE2),
are
highly
enriched
overexpression
positively
correlated
patients.
Both
have
ability
to
signal
COX-2
PGE2
axis
respond
autocrine/paracrine
manner.
enhanced
COX-2/PGE2
leads
pleotropic
effects
impact
dynamics
progression.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(2), P. 397 - 397
Published: Jan. 17, 2024
GBM
accounts
for
most
of
the
fatal
brain
cancer
cases,
making
it
one
deadliest
tumor
types.
is
characterized
by
severe
progression
and
poor
prognosis
with
a
short
survival
upon
conventional
chemo-
radiotherapy.
In
order
to
improve
therapeutic
efficiency,
considerable
efforts
have
been
made
target
various
features
GBM.
One
targetable
rewired
lipid
metabolism
that
contributes
tumor’s
aggressive
growth
penetration
into
surrounding
tissue.
Lipid
reprogramming
allows
acquire
survival,
proliferation,
invasion
benefits
as
well
supportive
modulation
microenvironment.
Several
attempts
find
novel
approaches
exploiting
metabolic
in
recent
studies,
components
de
novo
lipogenesis,
fatty
acid
oxidation,
uptake,
prostaglandin
synthesis
considered
promising
targets
Emerging
data
also
suggest
significant
role
hence
potential
endocannabinoid
pathway
Here
we
review
lipid-related
characteristics
detail
highlight
specific
their
use
antitumor
approaches.
